ACST stock news

LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 … Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc (NASDAQ: ARRY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 18) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Hologic, Inc. (NASDAQ: HOLX ) Novocure Ltd (NASDAQ: NVCR ) Odonate Therapeutics Inc (NASDAQ: ODT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 29) Acer Therapeutics Inc (NASDAQ: ACER ) Advaxis, Inc. (NASDAQ: ADXS ) Cancer Genetics Inc (NASDAQ: CGIX ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Genprex Inc (NASDAQ: GNPX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX )(slumped in reaction to Sanofi SA (NASDAQ: SNY )'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes) Myovant Sciences Ltd (NYSE: MYOV ) Neovasc Inc (NASDAQ: NVCN ) Neon Therapeutics Inc (NASDAQ: NTGN ) Neuralstem, Inc. (NASDAQ: CUR ) Novavax, Inc. (NASDAQ: NVAX ) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Personalis Inc (NASDAQ: PSNL )( IPOed June 20) Cytori Therapeutics (NASDAQ: PSTV ) Proteostasis Therapeutics Inc (NASDAQ: PTI ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Unity Biotechnology Inc (NASDAQ: UBX ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Wave Life Sciences Ltd (NASDAQ: WVE ) (reacted … Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems Inc (NASDAQ: CSII ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Masimo Corporation (NASDAQ: MASI ) VolitionRX Ltd (NYSE: VNRX ) Edwards Lifesciences Corp (NYSE: EW )(reported a beat-and-raise second quarter) Haemonetics Corporation (NYSE: HAE ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 24) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) GENFIT S A/ADR (NASDAQ: GNFT ) ContraVir Pharmaceuticals Inc (NASDAQ: HEPA) Innoviva Inc (NASDAQ: INVA ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Neovasc Inc (NASDAQ: NVCN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pluristem Therapeutics Inc. (NASDAQ: PSTI )(announced 1-for-10 reverse stock split) Regulus Therapeutics Inc (NASDAQ: RGLS )(FDA imposed partial clinical hold on its kidney disease drug) Surface Oncology Inc (NASDAQ: SURF ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Wave Life Sciences Ltd (NASDAQ: WVE ) Stocks In Focus FDA Approves Lilly's Nasally-Administered Low Blood Sugar Drug Eli Lilly And Co (NYSE: LLY ) said the FDA has approved its Baqsimi, the first and only nasally administered glucagon to treat severe hypoglycemia in a single, fixed, 3mg dose. Read more

Shares of biopharmaceutical company Acasti Pharma Inc (NASDAQ: ACST ) were trading higher Wednesday after the biopharmaceutical company issued a fiscal 2019 year-end business update. What Happened Acasti , a biopharma innovator focused on the treatment of severe hypertriglyceridemia (HTG), said in a business update that fiscal 2019 was "eventful." The company recorded milestones related to its Phase 3 clinical trials and achieved 100% patient randomization in the TRILOGY clinical trials. Acasti's loss for fiscal 2019 expanded from $21.5 million in the prior … Full story available on Benzinga.com Read more

LAVAL, Québec, May 10, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has settled regarding claims made against the Company by its former chief executive officer (the “Former CEO”) in respect of the termination of his employment Read more

Read more

LAVAL, Quebec, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- More Than 40% of Patients Have Completed Their 6 Month Treatment Plan Top Line Results Remain On… Read more

As Biotechnology businesses, Halozyme Therapeutics Inc. (NASDAQ:HALO) and Acasti Pharma Inc. (NASDAQ:ACST), are affected by contrast. This especially applies to their profitability, analyst recommenda Read more

Investors may be focusing on technical signals for Acasti Pharma (ACST). Looking at the reading from the 20-day moving average vs price signal, we can see that the signal is showing Sell. This is the Read more

Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal LAVAL, Québec,. Read more

The Ultimate Oscillator level is currently above 60 on shares of Acasti Pharma (ACST). Active traders may be closely following the indicator to see if overbought conditions are present at current leve Read more

Investors may be interested in following the opinion signal on shares of Acasti Pharma (ACST). For the current trading period, we can see that the opinion signal on the stock is 8% Buy. Heading back f Read more

Acasti Pharma Inc. (NASDAQ:ACST) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) have been rivals in the Biotechnology for quite some time. Below is a review of Read more

We are comparing Acasti Pharma Inc. (NASDAQ:ACST) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and v Read more